阿拉比多普西斯地图酶4负面调节系统性获得性耐药性
M Petersen1, P Brodersen, H Naested
1Institute of Molecular Biology, Copenhagen University, Oster Farimagsgade 2A, 1353 Copenhagen K, Denmark.
Cell
|February 13, 2001
概括
阿拉比多普西斯的突变mpk4通过增加酸 (SA) 水平,构成性地激活了全身获得的耐药性 (SAR). MPK4激酶活性对于抑制SAR和莉酸敏感基因表达是必不可少的.
科学领域:
- 植物分子生物学 植物分子生物学
- 植物免疫力 植物免疫力
- 阿拉比多普西斯研究研究
背景情况:
- 系统性获得性耐药性 (SAR) 是一种关键的植物防御机制.
- 植物免疫中的基激活蛋白激酶4 (MPK4) 作用尚未完全理解.
研究的目的:
- 研究MPK4在调节植物防御反应中的作用.
- 确定MPK4在系统性获得性耐药性 (SAR) 和激素信号传递中的作用.
主要方法:
- 在Arabidopsis中通过转子体无活化产生mpk4突变.
- 利用北方和微阵列杂交来进行基因表达分析.
- 分析了表达NahG的mpk4突变体和mpk4/npr1双突变体.
主要成果:
- mpk4突变体表现出构成性SAR,升高的酸 (SA) 水平,以及对病原体的增强抵抗力.
- 抑制SAR需要MPK4激酶活性;不活跃的MPK4无法补充突变物.
- 在mpk4中的SAR是SA-依赖的,但独立于NPR1.
- 在表达NahG. NahG.的mpk4突变体中,雅斯蒙酸诱导的基因表达 (PDF1.2,THI2.1) 被阻断.
结论:
- MPK4充当了Arabidopsis中的系统性获得性耐药性 (SAR) 的负调节者.
- MPK4对于对莉酸敏感的基因表达是必不可少的.
- SA信号通路对于MPK4介导的植物免疫调节至关重要.
相关概念视频
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...


